soul trial oral semaglutide cardiovascular outcomes 2024 nejm results Forecasting Milestones: A Predictive Analysis for Early Termination of the Study | Diabetes Therapy Oral Semaglutide and Cardiovascular Outcomes
Description
Seismologists first reported it as a 2.8 event, but later downgraded it to 2.5
Omental milky spots develop in the absence of lymphoid tissue-inducer cells and support B and T cell responses to peritoneal antigens
Future trials could help elucidate other potential benefits of GLP-1 drugs beyond sugar control
It contains semaglutide, a medication initially used to treat diabetes but was found to be effective in weight loss and weight management
Donaldson, G
Many individuals see significant weight loss after six months
